Navigation Links
The Lancet: New trial suggests cheaper drugs for common heart attack procedure could improve outcomes and save health budgets millions
Date:7/4/2014

A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes (such as a reduced rate of repeat heart attacks), compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries, and is around 400 times more expensive than heparin.

The results of the HEAT-PPCI trial suggest that systematic use of heparin rather than bivalirudin after primary percutaneous coronary intervention (PPCI) the most commonly used treatment for heart attack, which unblocks the arteries carrying blood to the heart could save health services substantial sums of money, at the same time as potentially improving patient outcomes.

Patients who undergo PPCI usually receive a combination of antithrombotic drugs to prevent any further blood clots forming during the procedure and after it has been completed. The most commonly used antithrombotic drugs are unfractionated heparin and bivalirudin, and although several previous trials have compared the two drugs, the evidence is unclear as to which drug results in better outcomes.

The trial took place at the Liverpool Heart and Chest Hospital in the UK, where 1829 patients undergoing emergency angiography (an x-ray examination of the heart's arteries after a suspected heart attack) were recruited to the trial. More than four fifths of these patients then went on to receive PPCI; approximately half received heparin, and half received bivalirudin. Researchers then recorded how many patients in both groups experienced a major adverse cardiac event, such as death or another heart attack, within 28 days after surgery.

The results show that overall rates of major adverse cardiac events were significantly lower in the group who received heparin, although the rates of adverse events were low, as expected, in both groups
'/>"/>

Contact: Matthew Back
matthew.back@lhch.nhs.uk
44-015-160-01423
The Lancet
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. The Lancet: Midwifery matters more than ever
2. The Lancet: UK has one of the highest death rates for children in western Europe
3. The Lancet: China halves tuberculosis prevalence in just 20 years
4. First evidence for painless atrial fibrillation treatment
5. ASPIRE Phase III trial of vaginal ring to prevent HIV completes enrollment of 2,629 women
6. GW leads clinical trial to reduce epileptic seizures in people with temporal lobe epilepsy
7. First first patient enrolled in PROSPECT II clinical trial
8. New definition of kidney disease for clinical trials could lead to new treatments
9. Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients
10. UH part of $7.5M NIH clinical trial on nearsightedness in children
11. Experimental trial represents promising step toward universal antidote for snakebite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... 27, 2014 The European Bromine market report ... and forecast of revenue. , Bromine market in European region ... and UK. Germany and France that forms a dominant share ... derivatives in Europe. , Browse through the TOC of ... the in-depth analysis provided Browse through the TOC of the ...
(Date:7/27/2014)... Australia (PRWEB) July 27, 2014 ... in Australia is restricted to two companies, heavy ... to IBISWorld industry analyst Spencer Little, “Demand for ... due to rising health concerns, frequent anti-smoking campaigns, ... result, industry revenue is estimated to fall at ...
(Date:7/27/2014)... 2014 iFitDress.com, a well-known wedding dress ... of wedding gowns with sleeves . Furthermore, it ... they are now available with big discounts, from 20 ... that iFitDress.com is one of the big players in ... the new wedding gowns feature fine craftsmanship and charming ...
(Date:7/27/2014)... Alta Resources , a global provider of ... brands, announced today that it plans to fill more ... Florida and the Philippines. , A majority of the ... seasonal ramp-ups that require additional staffing in preparation for ... 2015. As more consumers become eligible for health-plan coverage ...
(Date:7/27/2014)... Individuals that have been involved in an ... the newly released ebook guide for how to ... help those struggling through the aftermath of personal injury due ... guide attempts to help individuals understand the legal process and ... of their doctors and an experienced attorney. , Contact ...
Breaking Medicine News(10 mins):Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Auto Accident Personal Injury Ebook Guide Released by The Jones Firm 2
... In some cases, an apple a day may keep the ... may also do the job. A new study by ... the use of Aspirin as a preventative measure for cardiovascular ... collected data from clinical trials that looked at whether taking ...
... 5 (HealthDay News) -- Small rural hospitals in the United ... patient outcomes than larger hospitals, a new study finds. ... beneficiaries in order to assess the care provided by critical ... care beds and are located more than 35 miles from ...
... ROCHESTER, Minn. For nearly two decades, the medical ... lightning-rod topic of stem cells, in particular the controversy ... years ago successfully "reprogrammed" adult body cells to become ... over. Those redirected cells, known as induced pluripotent cells, ...
... HealthDay Reporter , TUESDAY, July 5 (HealthDay News) ... for easing low back pain in the short term, a ... mostly middle-aged, female and white, all of whom had chronic ... of either relaxation massage or structural massage were better able ...
... More breast cancer patients than previously believed may ... of Michigan Comprehensive Cancer Center study shows. Researchers ... whether cancer patients receive appropriate care and found that ... cancer patients undergo radiation treatments. The Surveillance ...
... Society invites you to attend the 2012 Symposium on ... held March 12-14, 2012, at the Marriott Baltimore Waterfront ... exciting first-time event. The symposium aims to bring ... and practice realms of the health-care community and to ...
Cached Medicine News:Health News:Higher daily dose of aspirin could play key role in preventing heart attacks for those with diabetes 2Health News:Small, Rural Hospitals Provide a Lower Quality of Care: Study 2Health News:Moving beyond embryonic stem cells: Encouragement on the horizon 2Health News:Massage Beats Meds for Lower Back Pain, Study Says 2Health News:Radiation rates for breast cancer may be underestimated, U-M study finds 2Health News:HFES sponsors 2012 Symposium on Human Factors and Ergonomics in Health Care 2
(Date:7/25/2014)... , July 25, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... June 30, 2014. "The second ... Semler," said Doug Murphy-Chutorian , M.D., chief ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: